R&D | November 25, 2025
Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025
Jaypirca is making waves in the fight against B-cell malignancies
Jaypirca is making waves in the fight against B-cell malignancies
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Globally, BRUKINSA is approved in more than 70 countries
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Comprehensive clinical development programs being initiated for each investigational candidate
Several late-stage pipeline products have the potential to address some of these unmet needs
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
It is developing the drug candidate to potentially treat immunological diseases
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Subscribe To Our Newsletter & Stay Updated
